SCHEMBL7185347

SCHEMBL7185347

COC(=O)C(C(=O)c1c(C)cccc1Cl)c1ccccc1.O=[PH3]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 3/20 0.43
MMP8 P22894 1/20 0.42
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.40
HTR1E P28566 1/20 0.40
S1PR3 Q99500 1/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
ALDH1A1 P00352 2/20 0.40
POLB P06746 1/20 0.40
FABP3 P05413 1/20 0.40
FABP4 P15090 1/20 0.40
TYK2 P29597 1/20 0.39
TRPM4 Q8TD43 1/20 0.39
MEN1 O00255 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
UTS2R Q9UKP6 1/20 0.37
PTGS1 P23219 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27484216 0.95 L3MBTL1 (0.43) L3MBTL1KMT2AMMP8MAPTLMNA
SCHEMBL7188536 0.92 KMT2A (0.47) L3MBTL1KMT2AMMP8MAPTLMNA
SCHEMBL7184953 0.91 MMP8 (0.50) L3MBTL1KMT2AMMP8MAPTLMNA
SCHEMBL7186423 0.90 L3MBTL1 (0.49) L3MBTL1KMT2AMMP8LMNAALDH1A1
SCHEMBL7184606 0.87 L3MBTL1 (0.42) L3MBTL1MMP8MAPTLMNAGAA
SCHEMBL7175796 0.86 L3MBTL1 (0.41) L3MBTL1KMT2AMMP8MAPTLMNA
SCHEMBL27499665 0.86 MMP8 (0.50) L3MBTL1KMT2AMMP8MAPTLMNA
SCHEMBL7189706 0.86 FABP4 (0.44) KMT2AMAPTLMNANPC1RAB9A
SCHEMBL7174628 0.85 ALDH1A1 (0.40) L3MBTL1KMT2AMMP8MAPTLMNA
SCHEMBL7182786 0.85 ELANE (0.43) L3MBTL1KMT2AMMP8MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 L3MBTL1 302/4885KMT2A 1586/4885MMP8 4404/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 L3MBTL1 126/4885KMT2A 956/4885MMP8 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.